Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
162 participants
OBSERVATIONAL
2016-12-31
2022-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
NCT00158249
Cannabinoids and Cerebellar-Motor Functioning
NCT01853020
Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
NCT00656487
SV2A in Older Adults
NCT05465538
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3
NCT06669585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cannabis Dependent Subjects
Subjects who are frequent cannabis users
[11-C]OMAR
The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Healthy Controls
Subjects with no current cannabis use
[11-C]OMAR
The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[11-C]OMAR
The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to abstain from cannabis use for four weeks
* No current cannabis consumption
Exclusion Criteria
* Education completed is less than 12 years
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohini Ranganathan
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohini Ranganathan, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Conneticut Mental Health Center
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1308012514
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.